Osimertinib in EGFR-Mutated Advanced NSCLC.
作者信息
Staege Martin S
机构信息
Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
出版信息
N Engl J Med. 2020 May 7;382(19):1863-1864. doi: 10.1056/NEJMc2001514.
PMID:32374971
Abstract
摘要
相似文献
1
Osimertinib in EGFR-Mutated Advanced NSCLC.
N Engl J Med. 2020 May 7;382(19):1863-1864. doi: 10.1056/NEJMc2001514.
2
Osimertinib in EGFR-Mutated Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌
N Engl J Med. 2020 May 7;382(19):1863. doi: 10.1056/NEJMc2001514.
3
Osimertinib in EGFR-Mutated Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌
N Engl J Med. 2020 May 7;382(19):1864. doi: 10.1056/NEJMc2001514.
4
Osimertinib in EGFR-Mutated Advanced NSCLC. Reply.奥希替尼用于表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌。回复。
N Engl J Med. 2020 May 7;382(19):1864-1865. doi: 10.1056/NEJMc2001514.
5
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.ADAURA 研究结果的简明报告：奥希替尼用于早期 EGFR 突变型非小细胞肺癌术后患者。
Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1.
6
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.ONO-7475，一种新型的 AXL 抑制剂，抑制了 - 突变非小细胞肺癌对初始 EGFR-TKI 治疗的适应性耐药。
Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.
7
Osimertinib in Resected EGFR-Mutated NSCLC.奥希替尼用于可切除的表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）
N Engl J Med. 2023 Oct 5;389(14):1341-1342. doi: 10.1056/NEJMc2309385.
8
Osimertinib in Resected EGFR-Mutated NSCLC. Reply.奥希替尼用于可切除的表皮生长因子受体突变型非小细胞肺癌。回复。
N Engl J Med. 2023 Oct 5;389(14):1342. doi: 10.1056/NEJMc2309385.
9
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1262. doi: 10.1056/NEJMc1801669.
10
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1261. doi: 10.1056/NEJMc1801669.
Zotero 插件